XORTX Historical Income Statement

Stocks . USA . 
Stock . XORTX Therapeutics
XRTX Stock  USD 1.27  0.06  4.96%   
Historical analysis of XORTX Therapeutics income statement accounts such as Selling General Administrative of 1 M, Other Operating Expenses of 2.4 M, Total Operating Expenses of 2.4 M or Depreciation And Amortization of 103.2 K can show how well XORTX Therapeutics performed in making a profits. Evaluating XORTX Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of XORTX Therapeutics's future profits or losses.
Cash Flow   Balance Sheet     Income Statement
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining XORTX Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether XORTX Therapeutics is a good buy for the upcoming year.

XORTX Therapeutics Net Income

(3 Million)

  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

About XORTX Income Statement Analysis

XORTX Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to XORTX Therapeutics shareholders. The income statement also shows XORTX investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Balance Sheet
Statement
Details
Cash Flow
Statement
Details
Financial
Indicators
Details
Valuation
Indicators
Details

XORTX Therapeutics Income Statement Chart

At this time, XORTX Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 3.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 1 M in 2024.
Selling General Administrative  Operating Income  Interest Expense  
Add Fundamental

Operating Income

Operating Income is the amount of profit realized from XORTX Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of XORTX Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.
Most accounts from XORTX Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into XORTX Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.At this time, XORTX Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 3.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 1 M in 2024.
 2021 2022 2023 2024 (projected)
Reconciled Depreciation17.9K55.5K139.7K146.7K
Research Development669.1K6.5M3.2M1.7M

XORTX Therapeutics income statement Correlations

Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Net Income
Depreciation And Amortization
Interest Expense
Total Other Income Expense Net
Income Tax Expense
Net Interest Income
Net Income From Continuing Ops
Research Development
Reconciled Depreciation
Interest Income
Selling And Marketing Expenses
Selling General Administrative
0.9-0.9-0.9-0.910.9-0.85-0.850.53-0.330.72-0.32-0.54-0.820.820.480.34-0.27
Other Operating Expenses
0.9-0.93-0.93-0.941.0-0.91-0.910.5-0.410.8-0.4-0.48-0.910.960.410.21-0.17
Operating Income
-0.9-0.931.01.0-0.930.880.88-0.750.53-0.910.510.360.83-0.94-0.69-0.520.49
Ebit
-0.9-0.931.01.0-0.930.880.88-0.750.53-0.910.510.360.83-0.94-0.69-0.520.49
Ebitda
-0.91-0.941.01.0-0.940.880.88-0.750.53-0.910.510.360.84-0.94-0.69-0.510.49
Total Operating Expenses
0.91.0-0.93-0.93-0.94-0.91-0.910.5-0.410.8-0.4-0.48-0.910.960.410.21-0.17
Income Before Tax
-0.85-0.910.880.880.88-0.911.0-0.570.27-0.630.250.260.98-0.89-0.49-0.30.3
Net Income
-0.85-0.910.880.880.88-0.911.0-0.570.27-0.630.250.260.98-0.89-0.49-0.30.3
Depreciation And Amortization
0.530.5-0.75-0.75-0.750.5-0.57-0.57-0.490.78-0.470.22-0.440.640.990.91-0.9
Interest Expense
-0.33-0.410.530.530.53-0.410.270.27-0.49-0.640.990.180.26-0.48-0.48-0.420.41
Total Other Income Expense Net
0.720.8-0.91-0.91-0.910.8-0.63-0.630.78-0.64-0.63-0.25-0.580.860.730.57-0.56
Income Tax Expense
-0.32-0.40.510.510.51-0.40.250.25-0.470.99-0.630.170.24-0.47-0.47-0.410.4
Net Interest Income
-0.54-0.480.360.360.36-0.480.260.260.220.18-0.250.170.36-0.280.250.33-0.32
Net Income From Continuing Ops
-0.82-0.910.830.830.84-0.910.980.98-0.440.26-0.580.240.36-0.87-0.35-0.150.15
Research Development
0.820.96-0.94-0.94-0.940.96-0.89-0.890.64-0.480.86-0.47-0.28-0.870.550.39-0.29
Reconciled Depreciation
0.480.41-0.69-0.69-0.690.41-0.49-0.490.99-0.480.73-0.470.25-0.350.550.94-0.93
Interest Income
0.340.21-0.52-0.52-0.510.21-0.3-0.30.91-0.420.57-0.410.33-0.150.390.94-0.83
Selling And Marketing Expenses
-0.27-0.170.490.490.49-0.170.30.3-0.90.41-0.560.4-0.320.15-0.29-0.93-0.83
Click cells to compare fundamentals

XORTX Therapeutics Account Relationship Matchups

High Positive Relationship

Total Operating Expenses
+ 1.0
Other Operating Expenses
Ebit
+ 1.0
Operating Income
Ebitda
+ 1.0
Operating Income
Ebitda
+ 1.0
Ebit
Net Income
+ 1.0
Income Before Tax
Reconciled Depreciation
+ 0.99
Depreciation And Amortization

High Negative Relationship

Research Development
- 0.94
Ebitda
Total Operating Expenses
- 0.94
Ebitda
Research Development
- 0.94
Ebit
Research Development
- 0.94
Operating Income
Ebitda
- 0.94
Other Operating Expenses
Selling And Marketing Expenses
- 0.93
Reconciled Depreciation

XORTX Therapeutics income statement Accounts

201920202021202220232024 (projected)
Selling General Administrative506.2K1.1M1.6M2.3M1.4M1.0M
Other Operating Expenses566.0K1.3M2.9M9.9M3.2M2.4M
Operating Income(566.0K)(1.3M)(4.1M)(10.7M)(6.6M)(6.2M)
Ebit(566.0K)(1.3M)(4.1M)(10.7M)(6.6M)(6.2M)
Ebitda(546.1K)(1.3M)(4.1M)(10.6M)(6.5M)(6.1M)
Total Operating Expenses566.0K1.3M2.9M9.9M3.2M2.4M
Income Before Tax(629.6K)(1.3M)(1.3M)(7.0M)(2.9M)(3.0M)
Net Income(629.6K)(1.3M)(1.3M)(7.0M)(2.9M)(3.0M)
Depreciation And Amortization19.9K16.0K14.0K55.5K98.3K103.2K
Interest Expense15.5K22.3K37.2K13.5K4.4K0.0
Total Other Income Expense Net(26.4K)(181.9K)1.6M5.5M3.7M3.9M
Income Tax Expense37.2K13.5K4.4K0.0(0.01)(0.0095)
Net Interest Income(37.2K)(13.5K)(1.6M)(825.4K)253.5K266.2K
Net Income From Continuing Ops(629.6K)(1.3M)(1.7M)(7.0M)(2.2M)(2.3M)
Research Development39.9K277.5K669.1K6.5M3.2M1.7M
Reconciled Depreciation19.9K20.4K17.9K55.5K139.7K146.7K
Net Income Applicable To Common Shares(629.6K)(1.3M)(1.7M)(9.5M)(8.5M)(8.1M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY